Grant Support

Current Grant Support

Cystic Fibrosis Foundation Therapeutics, Inc. and Seattle Children’s Hospital, “A long-term prospective observational safety study of the incidence of and risk factors for fibrosing colonopathy in US patients with cystic fibrosis treated with pancreatic enzyme replacement therapy: a harmonized protocol across sponsors (CFFC-OB-11)” (2012-2022).  Rock, site PI

Vertex Pharmaceuticals, Inc. (VX16-809-122), “A phase 3, 2-part, open-label study to evaluate the safety and pharmacokinetics of Lumacaftor/Ivacaftor in subjects 1 to less than 2 years of age with cystic fibrosis, homozygous for F508del” (2018-ongoing). Rock, PI

NIH/NIDDK (R01 DK109692), “Early childhood diet, growth, gut microbiome and lung health in cystic fibrosis” (2016-2021).  Rock, Co-Investigator

Cystic Fibrosis Foundation Therapeutics & Seattle Children’s Hospital, “Characterizing CFTR modulated changes in sweat chloride & clinical outcomes” (2017-ongoing). Rock, site PI

Vertex Pharmaceuticals, Inc. (VX15-770-126), “A phase 3, 2-arm, open-label study to evaluate the safety and pharmacodynamics of long-term Ivacaftor treatment in subjects with cystic fibrosis who are less than 24 months of age at treatment initiation and have a CFTR gating mutation” (2017-ongoing). Rock, PI

Cystic Fibrosis Foundation, “Impact of early malnutrition on lung disease development in cystic fibrosis,” (2017-2020). Rock, Co-Investigator

Vertex Pharmaceuticals, Inc. (VX15-809-110), “A phase 3, rollover study to evaluate the safety and efficacy of long-term treatment with Lumacaftor in combination with Ivacaftor in subjects aged 6 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation” (2016-ongoing).  Rock, PI

Vertex Pharmaceuticals, Inc. (VX15-770-124), “A phase 3, 2-part, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of Ivacaftor in subjects with cystic fibrosis who are less than 24 months of age at treatment initiation and have a CFTR gating mutation” (2016-ongoing).  Rock, PI

Cystic Fibrosis Foundation Therapeutics, Inc., “Therapeutics development center” (2009-ongoing).  Rock, PI

Cystic Fibrosis Foundation Therapeutics, Inc. and Seattle Children’s Hospital, “EPIC-002: Longitudinal assessment of risk factors for and impact of pseudomonas aeruginosa acquisition and early anti-pseudomonal treatment in children with CF” (2005-ongoing).  Rock, PI

Cystic Fibrosis Foundation, “Cystic fibrosis center” (2005-ongoing).  Rock, Director

Wisconsin Department of Health Services, “Congenital disorders program: Cystic fibrosis newborn screening” (2004-ongoing).  Rock, PI

Cystic Fibrosis Foundation Therapeutics, “ARC – Additional research coordinator award” (2016-2019).  Rock, PI


Completed Grant Support

Cystic Fibrosis Foundation, “First and second year clinical fellowship grant, Christina Barreda” (2016-2018).  Rock, Primary Sponsor

NIH/NHLBI (U01 HL114623), “The OPTIMIZE multicenter, placebo-controlled, double-blind, randomized trial optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis” (2014-2018).  Rock, Site PI

Legacy of Angels Foundation, “A multi-center study of a new method of sweat testing: the CF quantum sweat test” (2015-2017).  Rock, PI

Legacy of Angels Foundation, “A prospective study of newborn screening for cystic fibrosis using a novel IRT/next generation sequencing method” (2014-2017).  Rock, Co-Investigator

NIH/NIDDK (R01 DK072126), “Newborn screening, malnutrition and lung disease in children with cystic fibrosis” (2011-2017).  Rock, Co-Investigator

Vertex Pharmaceuticals, Inc., “Lumacaftor/Ivacaftor combination therapy expanded access program for patients 12 years of age and older with cystic fibrosis who are homozygous for the F508del-CFTR mutation” (2016).  Rock, PI

Vertex Pharmaceuticals, Inc. (VX14-809-109), “A phase 3, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Lumacaftor in combination with Ivacaftor in subjects aged 6 through 11 years with cystic fibrosis, homozygous for the F508del-CFTR mutation” (2015-2016).  Rock, PI

NIH/NIDDK (R56 DK109692), “Early childhood diet, growth, gut microbiome and lung disease in cystic fibrosis” (2015-2016).  Rock, Co-Investigator

Cystic Fibrosis Foundation & University of North Carolina – Chapel Hill, “Variability in sweat testing assays (VISTA)” (2015-2016).  Rock, Co-Investigator

Cystic Fibrosis Foundation, “Fundamentals LLC” (2015-2016).  Rock, PI

Cystic Fibrosis Foundation Therapeutics, Inc. and Seattle Children’s Hospital, “A multi-center, randomized, controlled, double-blind study of the effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in cystic fibrosis patients (AquADEKs)” (2013-2016).  Rock, PI

KaloBios Pharmaceuticals, Inc., “A phase 2, randomized, doulbe-blind, placebo-controlled, repeat-dose study of KB001-A in subjects with cystic fibrosis infected with pseudomonas aeruginosa” (2013-2015).  Rock, PI

Registrat, Inc., “A point-prevalence study to evaluate the prevalence of antibodies to selected porcine viruses in patients with cystic fibrosis who are receiving porcine-derived pancreatic enzyme replacement therapy: a harmonized protocol across sponsors (VTPP)” (2013-2015).  Rock, PI

Legacy of Angels Foundation, “Quality improvement in cystic fibrosis newborn screening—addressing the sweat test QNS problem with a novel method” (2012-2014).  Rock, Co-PI

Cystic Fibrosis Foundation, “First and second year clinical fellowship grants for Kelly Cowan” (2010-2013).  Rock, Primary Sponsor

NIH/NIDDK (R01 DK034108), “Pulmonary benefits of cystic fibrosis neonatal screening” (2007-2012).  Rock, Co-Investigator

Inspire Pharmaceuticals, Inc., “Study 08-114: open-label extension of study 08-110 – a multi-center study of denufosol tetrasodium inhalation solution in patients with cystic fibrosis lung disease” (2010-2011).  Rock, PI.

Cystic Fibrosis Foundation Therapeutics, Inc. and University of North Carolina-Chapel Hill, “Infant study of inhaled saline in cystic fibrosis” (2008-2011).  Rock, PI

NIH/NIDDK (R01 DK072126), “Malnutrition and lung disease in cystic fibrosis” (2006-2011).  Rock, Co-Investigator

Axcan Pharma, “Efficacy and safety of ultrase MT12 in the control of steatorrhea in children with cystic fibrosis and pancreatic insufficiency” (2009-2010).  Rock, PI

Inspire Pharmaceuticals, Inc., A phase 3, international, multi-center, randomized, double-blind, placebo-controlled parallel-group, efficacy and safety study of denufosol tetrasodium inhalation solution in patients with cystic fibrosis lung disease and FEV1 ≥75% but ≤110% predicted” (2008-2010).  Rock, PI

Cystic Fibrosis Foundation, “First and second year clinical fellowship grant for Benjamin Tippets” (2007-2009).  Rock, Primary Sponsor

Inspire Pharmaceuticals, “A multi-center, double-blind, placebo-controlled randomized, efficacy and safety study of denufosol tetrasodium (INS37217) inhalation solution in patients with mild cystic fibrosis lung disease” (2006-2009).  Rock, PI

NIH, Cystic Fibrosis Foundation Therapeutics, Inc. and Seattle Children’s Hospital, “EPIC-001: effectiveness and safety of intermittent antimicrobial therapy of the treatment of new onset pseudomonas aeruginosa airway infection in young patients with cystic fibrosis” (2005-2009).  Rock, PI

NIH, Cystic Fibrosis Foundation and Johns Hopkins University, “Genetic modifiers of cystic fibrosis” (2001-2009).  Rock, site PI

Cystic Fibrosis Foundation, “Clinical research facilitation award” (2006-2007).  Rock, PI

Nemours Foundation, “Managed care and access to healthcare for CF children” (1997-2006).  Rock, PI

Salus Pharma, Inc., “A blinded, multicenter, randomized, placebo-controlled trial with aztreonam for inhalation (AI) in cystic fibrosis patients with lung disease due to p. aeruginosa infection” (2003-2004).  Rock, PI

Boehringer Ingelheim Ltd., “a randomized, double-blind, placebo controlled study to investigate the efficacy & safety of 24 weeks of oral treatment with BIIL 284 BS in adult (75 mg, 150 mg) and pediatric (75 mg) cystic fibrosis patients” (2003-2004).  Rock, PI